BRIEF-Biofrontera Announces New Patent Protection On Ameluz Until 2043

Reuters
16 May
BRIEF-Biofrontera Announces New Patent Protection On Ameluz Until 2043

May 15 (Reuters) - Biofrontera Inc BFRI.O:

  • BIOFRONTERA INC. ANNOUNCES NEW PATENT PROTECTION ON AMELUZ® UNTIL 2043 AND THE COMPLETION OF PATIENT ENROLLMENT IN PHASE 2B STUDY OF AMELUZ® (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS

  • BIOFRONTERA INC - EXPECTS LAST-PATIENT-OUT IN Q3 2025 FOR AMELUZ TRIAL

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10